Lacosamide
MOTPOLY XR, Vimpat
Anticonvulsant
NADAC/unit
$0.0951
No Shortage
Tier 1: 84.5%
PA Req: 3.6%
28 Manufacturers
71 ANDAs
indicated for: Treatment of partial-onset seizures in patients 4 years of age and older (1.1) Adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients 4 years of....
vs. brand MOTPOLY XR: Generic saves up to 99% per unit
Market Intelligence
2025-04-16 Class II Recall: Glenmark Pharmaceuticals Inc., USA
2025-04-16 Class II Recall: Glenmark Pharmaceuticals Inc., USA
2025-04-16 Class II Recall: Glenmark Pharmaceuticals Inc., USA
2025-04-16 Class II Recall: Glenmark Pharmaceuticals Inc., USA
Generic Manufacturers
ACELLA PHARMACEUTICALS LLCAJENAT PHARMACEUTICALS LLCALEMBIC PHARMACEUTICALS LTDALKEM LABORATORIES LTDANTHEA PHARMA PRIVATE LTDAPOTEX INCASPIRO PHARMA LTDAUCTA PHARMACEUTICALS INCAUROBINDO PHARMA LTDCHARTWELL RX SCIENCES LLCDR REDDYS LABORATORIES LTDFRESENIUS KABI USA LLCGLAND PHARMA LTDGLENMARK PHARMACEUTICALS LTDHAINAN POLY PHARM CO LTDHETERO LABS LTD UNIT IIIHETERO LABS LTD UNIT VHIKMA PHARMACEUTICALS USA INCKANCHAN HEALTHCARE INCMACLEODS PHARMACEUTICALS LTDMSN LABORATORIES PRIVATE LTDNOVITIUM PHARMA LLCREGCON HOLDINGS LLCSCIEGEN PHARMACEUTICALS INCSOMERSET THERAPEUTICS LLCSUN PHARMACEUTICAL INDUSTRIES LTDUCB INCUNICHEM LABORATORIES LTDWESTMINSTER PHARMACEUTICALS LLCZYDUS PHARMACEUTICALS USA INC
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.